Altria Group Inc. Stock Outperforms Competitors Despite Losses On The Day
MarketWatch Automated·Best Pharmaceutical Stocks To Watch Today - August 21st
Market Beat·- MarketBeat identified seven pharmaceutical stocks with the highest dollar trading volume to watch, including Eli Lilly, Merck, Johnson & Johnson, AbbVie, Pfizer, Abbott Laboratories, and Jupiter Neurosciences. - These publicly traded companies operate globally in discovering, developing, manufacturing, and selling prescription and over-the-counter medicines across diverse therapeutic areas. - While these pharmaceutical stocks offer growth potential through successful drug approvals and strong sales, they also carry inherent risks related to clinical trials, regulatory decisions, patents, and pricing pressures.Global Retirement Partners LLC Makes New $4.34 Million Investment in Pfizer Inc. $PFE
Market Beat·- Global Retirement Partners LLC acquired a new position of 180,182 shares in Pfizer Inc. valued at approximately $4.34 million during the 2nd quarter. - Pfizer recently reported second-quarter earnings with an EPS of $0.77 and revenue of $15.03 billion, outperforming analyst estimates. - The company faces mixed market sentiment driven by institutional investments, high dividend yields, legal settlements, and challenges related to its upcoming patent cliff.3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth
PR Newswire·- 3SBio reported its 2026 interim results, posting a revenue of RMB 4.53 billion and an adjusted operating net profit of RMB 1.44 billion, representing a 26.5% year-over-year increase. - The company advanced its innovation pipeline by securing marketing approvals for three Class 1 innovative drugs, advancing five products to the New Drug Application stage, and driving global clinical trials for PF-08634404. - 3SBio also expanded its multi-therapeutic portfolio across oncology, autoimmune diseases, and nephrology, while its Wind ESG rating was upgraded to "AA" for its sustainable development practices.Sunshine Guojian Releases 2026 Interim Report:
PR Newswire·- Sunshine Guojian released its 2026 interim report, recording RMB 866 million in total operating revenue and RMB 371 million in net profit attributable to equity holders. - The company advanced its R&D pipeline and secured approvals for products including Yisaituo® and Yisaina®, while expanding global clinical trials through external collaboration. - This performance reflects robust financial growth and strategic progress, reinforcing the company's market position in antibody therapeutics and autoimmune diseases.Pfizer (NYSE:PFE) Shares Down 1.5% - Should You Sell?
Market Beat·- Pfizer shares fell 1.5% to $27.83 amid market developments, including litigation settlements and a race between new product pipelines and patent expirations. - The company reported second-quarter earnings of $0.77 per share on revenue of $15.03 billion, outperforming Wall Street consensus estimates. - Major institutional investors like Vanguard and BlackRock adjusted their stakes, while analysts maintained a consensus Hold rating with a target price of $28.28.Altria Group Inc. Stock Outperforms Competitors On Strong Trading Day
MarketWatch Automated·